ALK inhibitor

DRUG CLASS:

ALK inhibitor

News alerts, weekly reports and conference planners

Related drugs:

EML4-ALK fusion	Neuroendocrine Tumor	EML4-ALK fusion	Neuroendocrine Tumor	alectinib Sensitive: C4 – Case Studies Ann Transl Med - 3 days (New C4) alectinib Sensitive : C4 Ann Transl Med - 3d	alectinib Sensitive: C4 – Case Studies Ann Transl Med - 3 days alectinib Sensitive : C4 Ann Transl Med - 3 days - (New C4)
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	TPX-0005 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 6 days (New C3) TPX-0005 Sensitive : C3 IASLC-TTLC 2023 - 6d	TPX-0005 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 6 days TPX-0005 Sensitive : C3 IASLC-TTLC 2023 - 6 days - (New C3)
ROS1 fusion + KRAS G12C	Non Small Cell Lung Cancer	ROS1 fusion + KRAS G12C	Non Small Cell Lung Cancer	entrectinib Resistant: C4 – Case Studies NPJ Precis Oncol - 1 week (New C4) entrectinib Resistant : C4 NPJ Precis Oncol - 1wk	entrectinib Resistant: C4 – Case Studies NPJ Precis Oncol - 1 week entrectinib Resistant : C4 NPJ Precis Oncol - 1 week - (New C4)
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week (New C4) alectinib Sensitive : C4 Anticancer Drugs - 1wk	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week alectinib Sensitive : C4 Anticancer Drugs - 1 week - (New C4)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1
No biomarker	Solid Tumor	No biomarker	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Small Intestinal Carcinoma	NTRK3 fusion	Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Small Intestinal Carcinoma	NTRK1 fusion	Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Small Intestinal Carcinoma	NTRK2 fusion	Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2
NTRK3 fusion	Soft Tissue Sarcoma	NTRK3 fusion	Soft Tissue Sarcoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Gastrointestinal Stromal Tumor	NTRK2 fusion	Gastrointestinal Stromal Tumor	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2

ALK inhibitor

ALK inhibitor

Associations(858)

Associations
(858)